메뉴 건너뛰기




Volumn 6, Issue 13, 2005, Pages 2231-2243

Drug-drug interactions of antifungal agents and implications for patient care

Author keywords

Antifungal agents; Azoles; Drug drug interactions; Echinocandins; Polyenes

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ATORVASTATIN; CARRIER PROTEIN; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450; DIAZEPAM; DIGOXIN; ECHINOCANDIN; FLUCONAZOLE; FLUOROURACIL; GLYCOPROTEIN P; ITRACONAZOLE; KETOCONAZOLE; LOOP DIURETIC AGENT; MEVINOLIN; MICAFUNGIN; MIDAZOLAM; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; SIMVASTATIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE;

EID: 27744597564     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.13.2231     Document Type: Review
Times cited : (47)

References (98)
  • 1
    • 0025256091 scopus 로고
    • Amphotericin B: 30 years of clinical experience
    • GALLIS HA, DREW RH, PICKARD WW: Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. (1990) 12(2):308-329.
    • (1990) Rev. Infect. Dis. , vol.12 , Issue.2 , pp. 308-329
    • Gallis, H.A.1    Drew, R.H.2    Pickard, W.W.3
  • 2
    • 0027321730 scopus 로고
    • Immunomodulating activity of antifungal drugs
    • YAMAGUCHI H, ABE S, TOKUDA Y: Immunomodulating activity of antifungal drugs. Ann. NY Acad. Sci. (1993) 685:447-457.
    • (1993) Ann. NY Acad. Sci. , vol.685 , pp. 447-457
    • Yamaguchi, H.1    Abe, S.2    Tokuda, Y.3
  • 3
    • 0028031883 scopus 로고
    • Oral azole drugs as systemic antifungal therapy
    • COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330(4):263-272.
    • (1994) N. Engl. J. Med. , vol.330 , Issue.4 , pp. 263-272
    • Como, J.A.1    Dismukes, W.E.2
  • 4
    • 0032927254 scopus 로고    scopus 로고
    • Drug, meal and formulation interactions influencing drug absorption after oral administration: Clinical implications
    • FLEISHER D, LI C, ZHOU Y, KARIM A: Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin. Pharmacokinet. (1999) 36(3):233-254.
    • (1999) Clin. Pharmacokinet. , vol.36 , Issue.3 , pp. 233-254
    • Fleisher, D.1    Li, C.2    Zhou, Y.3    Karim, A.4
  • 6
    • 0024847184 scopus 로고
    • The clinical pharmacokinetics of itraconazole: An overview
    • HEYKANTS J, VAN PEER A, VAN DE VELDE V et al.: The clinical pharmacokinetics of itraconazole: an overview. Mycoses (1989) 32(Suppl. 1):67-87.
    • (1989) Mycoses , vol.32 , Issue.SUPPL. 1 , pp. 67-87
    • Heykants, J.1    Van Peer, A.2    Van De Velde, V.3
  • 9
    • 0037371527 scopus 로고    scopus 로고
    • Voriconazole: A new triazole antifungal agent
    • JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630-637.
    • (2003) Clin. Infect. Dis. , vol.36 , Issue.5 , pp. 630-637
    • Johnson, L.B.1    Kauffman, C.A.2
  • 10
    • 0037403687 scopus 로고    scopus 로고
    • Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
    • HYLAND R, JONES BC, SMITH DA: Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Disp. (2003) 31(5):540-547.
    • (2003) Drug Metab. Disp. , vol.31 , Issue.5 , pp. 540-547
    • Hyland, R.1    Jones, B.C.2    Smith, D.A.3
  • 11
    • 0034792584 scopus 로고    scopus 로고
    • Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
    • GOLDSTEIN JA: Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. (2001) 52(4):349-355.
    • (2001) Br. J. Clin. Pharmacol. , vol.52 , Issue.4 , pp. 349-355
    • Goldstein, J.A.1
  • 12
    • 0036263813 scopus 로고    scopus 로고
    • Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in vitro and human data
    • LEE CR, GOLDSTEIN JA, PIEPER JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics (2002) 12(3):251-263.
    • (2002) Pharmacogenetics , vol.12 , Issue.3 , pp. 251-263
    • Lee, C.R.1    Goldstein, J.A.2    Pieper, J.A.3
  • 14
    • 0031748173 scopus 로고    scopus 로고
    • In vitro and in vivo drug interactions involving human CYP3A
    • THUMMEL KE, WILKINSON GR: In vitro and in vivo drug interactions involving human CYP3A. Ann. Rev. Pharmacol. Toxicol. (1998) 38:389-430.
    • (1998) Ann. Rev. Pharmacol. Toxicol. , vol.38 , pp. 389-430
    • Thummel, K.E.1    Wilkinson, G.R.2
  • 15
    • 0031423883 scopus 로고    scopus 로고
    • Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro
    • OMAR G, WHITING PH, HAWKSWORTH GM, HUMPHREY MJ, BURKE MD: Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther. Drug Monit. (1997) 19(4):436-445.
    • (1997) Ther. Drug Monit. , vol.19 , Issue.4 , pp. 436-445
    • Omar, G.1    Whiting, P.H.2    Hawksworth, G.M.3    Humphrey, M.J.4    Burke, M.D.5
  • 16
    • 0036957299 scopus 로고    scopus 로고
    • Voriconazole in the treatment of invasive aspergillosis
    • MUIJSERS RB, GOA KL, SCOTT LJ: Voriconazole in the treatment of invasive aspergillosis. Drugs (2002) 62(18):2655-2664.
    • (2002) Drugs , vol.62 , Issue.18 , pp. 2655-2664
    • Muijsers, R.B.1    Goa, K.L.2    Scott, L.J.3
  • 17
    • 0029996292 scopus 로고    scopus 로고
    • Warfarin-fluconazole II. A metabolically based drug interaction: In vivo studies
    • BLACK DJ, KUNZE KL, WIENKERS LC et al.: Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab. Disp. (1996) 24(4):422-428.
    • (1996) Drug Metab. Disp. , vol.24 , Issue.4 , pp. 422-428
    • Black, D.J.1    Kunze, K.L.2    Wienkers, L.C.3
  • 19
    • 0029028792 scopus 로고
    • Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
    • WACHER VJ, WU CJ, BENET LZ: Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinogen. (1995) 13(3):129-134.
    • (1995) Mol. Carcinogen. , vol.13 , Issue.3 , pp. 129-134
    • Wacher, V.J.1    Wu, C.J.2    Benet, L.Z.3
  • 20
    • 0031765907 scopus 로고    scopus 로고
    • Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics
    • WACHER VJ, SILVERMAN JA, ZHANG Y, BENET LZ: Role of P-glycoprotein and cytochrome P450 in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. (1998) 87(11):1322-1330.
    • (1998) J. Pharm. Sci. , vol.87 , Issue.11 , pp. 1322-1330
    • Wacher, V.J.1    Silverman, J.A.2    Zhang, Y.3    Benet, L.Z.4
  • 21
    • 0345411341 scopus 로고    scopus 로고
    • P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies
    • WANDEL C, KIM RB, KAJIJI S, GUENGERICH P, WILKINSON GR, WOOD AJ: P-glycoprotein and cytochrome P450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. (1999) 59(16):3944-3948.
    • (1999) Cancer Res. , vol.59 , Issue.16 , pp. 3944-3948
    • Wandel, C.1    Kim, R.B.2    Kajiji, S.3    Guengerich, P.4    Wilkinson, G.R.5    Wood, A.J.6
  • 22
    • 17544365536 scopus 로고    scopus 로고
    • The role of passive transbilayer drug movement in multidrug resistance and its modulation
    • EYTAN GD, REGEV R, OREN G, ASSARAF YG: The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. (1996) 271(22):12897-12902.
    • (1996) J. Biol. Chem. , vol.271 , Issue.22 , pp. 12897-12902
    • Eytan, G.D.1    Regev, R.2    Oren, G.3    Assaraf, Y.G.4
  • 23
    • 0033969525 scopus 로고    scopus 로고
    • Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane
    • FERTE J: Analysis of tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. (2000) 267(2):277-294.
    • (2000) Eur. J. Biochem. , vol.267 , Issue.2 , pp. 277-294
    • Ferte, J.1
  • 24
    • 0344512413 scopus 로고    scopus 로고
    • Voriconazole does not affect the steady-state pharmacokinetics of digoxin
    • PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole does not affect the steady-state pharmacokinetics of digoxin. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):45-50.
    • (2003) Br. J. Clin. Pharmacol. , vol.56 , Issue.SUPPL. 1 , pp. 45-50
    • Purkins, L.1    Wood, N.2    Kleinermans, D.3    Nichols, D.4
  • 25
    • 0033787342 scopus 로고    scopus 로고
    • Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine
    • BALANI SK, XU X, ARISON BH, SILVA MV, GRIES A, DELUNA FA et al.: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Disp. (2000) 28(11):1274-1278.
    • (2000) Drug Metab. Disp. , vol.28 , Issue.11 , pp. 1274-1278
    • Balani, S.K.1    Xu, X.2    Arison, B.H.3    Silva, M.V.4    Gries, A.5    Deluna, F.A.6
  • 27
    • 4644320394 scopus 로고    scopus 로고
    • Micafungin
    • CARVER PL: Micafungin. Ann. Pharmacotherapy (2004) 38(10):1707-1721.
    • (2004) Ann. Pharmacotherapy , vol.38 , Issue.10 , pp. 1707-1721
    • Carver, P.L.1
  • 28
    • 0003339063 scopus 로고    scopus 로고
    • A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen
    • Toronto, Ontario, Canada Abstract 854
    • STONE JA, MCCREA JB, WICKERSHAM PJ et al.: A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. Program & Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) Abstract 854.
    • (2000) Program & Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Stone, J.A.1    McCrea, J.B.2    Wickersham, P.J.3
  • 29
    • 0028273122 scopus 로고
    • Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole
    • ZIMMERMAN T, YEATES RA, LAUFEN H, PFAFF G, WILDFEUER A: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol. (1994) 46(2):147-150.
    • (1994) Eur. J. Clin. Pharmacol. , vol.46 , Issue.2 , pp. 147-150
    • Zimmerman, T.1    Yeates, R.A.2    Laufen, H.3    Pfaff, G.4    Wildfeuer, A.5
  • 30
    • 0037326511 scopus 로고    scopus 로고
    • A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution
    • JOHNSON MD, HAMILTON CD, DREW RH, SANDERS LL, PENNICK GJ, PERFECT JR: A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. J. Antimicrob. Chemother. (2003) 51(2):453-457.
    • (2003) J. Antimicrob. Chemother. , vol.51 , Issue.2 , pp. 453-457
    • Johnson, M.D.1    Hamilton, C.D.2    Drew, R.H.3    Sanders, L.L.4    Pennick, G.J.5    Perfect, J.R.6
  • 31
    • 0031765677 scopus 로고    scopus 로고
    • Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: The effect of famotidine on the absorption of itraconazole
    • KANDA Y, KAMI M, MATSUYAMA T et al.: Plasma concentrations of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol. Oncol. (1998) 16(1):33-37.
    • (1998) Hematol. Oncol. , vol.16 , Issue.1 , pp. 33-37
    • Kanda, Y.1    Kami, M.2    Matsuyama, T.3
  • 32
    • 0027175695 scopus 로고
    • Short report: The absorption of fluconazole and itraconazole under conditions of low intragastric acidity
    • LIM SG, SAWYERR AM, HUDSON M, SERCOMBE J, POUNDER RE: Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol. Ther. (1993) 7(5):317-321.
    • (1993) Aliment. Pharmacol. Ther. , vol.7 , Issue.5 , pp. 317-321
    • Lim, S.G.1    Sawyerr, A.M.2    Hudson, M.3    Sercombe, J.4    Pounder, R.E.5
  • 33
    • 0031922837 scopus 로고    scopus 로고
    • Effect of omeprazole on the pharmacokinetics of itraconazole
    • JARURATANASIRIKUL S, SRIWIRIYAJAN S: Effect of omeprazole on the pharmacokinetics of itraconazole. Eur. J. Clin. Pharmacol. (1998) 54(2):159-161.
    • (1998) Eur. J. Clin. Pharmacol. , vol.54 , Issue.2 , pp. 159-161
    • Jaruratanasirikul, S.1    Sriwiriyajan, S.2
  • 34
    • 0028060606 scopus 로고
    • Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers
    • MAY DB, DREW RH, YEDINAK KC, BARLETT JA: Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy (1994) 14(5):509-513.
    • (1994) Pharmacotherapy , vol.14 , Issue.5 , pp. 509-513
    • May, D.B.1    Drew, R.H.2    Yedinak, K.C.3    Barlett, J.A.4
  • 35
    • 0036097706 scopus 로고    scopus 로고
    • Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole
    • DAMLE B, HESS H, KAUL S, KNUPP C: Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm. Drug Disp. (2002) 23(2):59-66.
    • (2002) Biopharm. Drug Disp. , vol.23 , Issue.2 , pp. 59-66
    • Damle, B.1    Hess, H.2    Kaul, S.3    Knupp, C.4
  • 36
    • 0031736655 scopus 로고    scopus 로고
    • Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
    • CHRISTIANS U, JACOBSEN W, FLOREN LC: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. (1998) 80(1):1-34.
    • (1998) Pharmacol. Ther. , vol.80 , Issue.1 , pp. 1-34
    • Christians, U.1    Jacobsen, W.2    Floren, L.C.3
  • 37
    • 0000626919 scopus 로고    scopus 로고
    • ZD4522-An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: Metabolic studies in human in vitro systems
    • [abstract]
    • MCCORMICK AD, MCKILLOP D, BUTTERS CJ et al.: ZD4522-An HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems [abstract]. J. Clin. Pharmacol. (2000) 40(10):1055.
    • (2000) J. Clin. Pharmacol. , vol.40 , Issue.10 , pp. 1055
    • McCormick, A.D.1    McKillop, D.2    Butters, C.J.3
  • 38
    • 0032911163 scopus 로고    scopus 로고
    • Comparison of cytochrome P450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver
    • JACOBSEN W, KIRCHNER G, HALLENSLEBEN K et al.: Comparison of cytochrome P450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-COA-reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab. Disp. (1999) 27(2):173-179.
    • (1999) Drug Metab. Disp. , vol.27 , Issue.2 , pp. 173-179
    • Jacobsen, W.1    Kirchner, G.2    Hallensleben, K.3
  • 39
    • 0032438509 scopus 로고    scopus 로고
    • Optimization of itraconazole therapy using target drug concentrations
    • POIRIER JM, CHEYMOL G: Optimization of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. (1998) 35(6):461-473.
    • (1998) Clin. Pharmacokinet. , vol.35 , Issue.6 , pp. 461-473
    • Poirier, J.M.1    Cheymol, G.2
  • 40
    • 0029758869 scopus 로고    scopus 로고
    • Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
    • NEUVONEN PJ, JALAVA KM: Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. (1996) 60(1):54-61.
    • (1996) Clin. Pharmacol. Ther. , vol.60 , Issue.1 , pp. 54-61
    • Neuvonen, P.J.1    Jalava, K.M.2
  • 41
    • 0031892901 scopus 로고    scopus 로고
    • Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
    • NEUVONEN PJ, KANTOLA T, KIVISTÖ KT: Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (1998) 63(3):332-341.
    • (1998) Clin. Pharmacol. Ther. , vol.63 , Issue.3 , pp. 332-341
    • Neuvonen, P.J.1    Kantola, T.2    Kivistö, K.T.3
  • 42
    • 0031847115 scopus 로고    scopus 로고
    • Effect of itraconazole on the pharmacokinetics of atorvastatin
    • KANTOLA T, KIVISTÖ KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther. (1998) 64(1):58-65.
    • (1998) Clin. Pharmacol. Ther. , vol.64 , Issue.1 , pp. 58-65
    • Kantola, T.1    Kivistö, K.T.2    Neuvonen, P.J.3
  • 43
    • 0033745108 scopus 로고    scopus 로고
    • Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
    • MAZZU AL, LASSETER KC, SHAMBLIN EC, AGARWAL V, LETTIERI J, SUNDARESEN P: Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin. Pharmacol. Ther. (2000) 68(4):391-400.
    • (2000) Clin. Pharmacol. Ther. , vol.68 , Issue.4 , pp. 391-400
    • Mazzu, A.L.1    Lasseter, K.C.2    Shamblin, E.C.3    Agarwal, V.4    Lettieri, J.5    Sundaresen, P.6
  • 44
    • 0034961379 scopus 로고    scopus 로고
    • Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions
    • ISHIGAM M, UCHIYAMA M, KONDO T et al.: Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and predictions of in vivo drug-drug interactions. Pharm. Res. (2001) 18(5):622-631.
    • (2001) Pharm. Res. , vol.18 , Issue.5 , pp. 622-631
    • Ishigam, M.1    Uchiyama, M.2    Kondo, T.3
  • 45
    • 0031803373 scopus 로고    scopus 로고
    • Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
    • KIVISTÖ KT, KANTOLA T, NEUVONEN PJ: Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br. J. Clin. Pharmacol. (1998) 46(1):49-53.
    • (1998) Br. J. Clin. Pharmacol. , vol.46 , Issue.1 , pp. 49-53
    • Kivistö, K.T.1    Kantola, T.2    Neuvonen, P.J.3
  • 47
    • 0032949332 scopus 로고    scopus 로고
    • Molecular and physical mechanisms of first-pass extraction
    • HALL SD, THUMMEL KE, WATKINS PB et al.: Molecular and physical mechanisms of first-pass extraction. Drug Metab. Disp. (1999) 27(2):161-166.
    • (1999) Drug Metab. Disp. , vol.27 , Issue.2 , pp. 161-166
    • Hall, S.D.1    Thummel, K.E.2    Watkins, P.B.3
  • 48
    • 0028568243 scopus 로고
    • Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole
    • VARHE A, OLKKOLA KT, NEUVONEN PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. (1994) 56(6):601-607.
    • (1994) Clin. Pharmacol. Ther. , vol.56 , Issue.6 , pp. 601-607
    • Varhe, A.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 49
    • 0029664974 scopus 로고    scopus 로고
    • The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    • OLKKOLA KT, AHONEN J, NEUVONEN PJ: The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg. (1996) 82(3):511-516.
    • (1996) Anesth. Analg. , vol.82 , Issue.3 , pp. 511-516
    • Olkkola, K.T.1    Ahonen, J.2    Neuvonen, P.J.3
  • 50
    • 0029810767 scopus 로고    scopus 로고
    • The effect of ingestion time interval on the interaction between itraconazole and triazolam
    • NEUVONEN PJ, VARHE A, OLKKOLA KT: The effect of ingestion time interval on the interaction between itraconazole and triazolam. Clin. Pharmacol. Ther. 1996 60(3):326-331.
    • (1996) Clin. Pharmacol. Ther. , vol.60 , Issue.3 , pp. 326-331
    • Neuvonen, P.J.1    Varhe, A.2    Olkkola, K.T.3
  • 51
    • 0031959294 scopus 로고    scopus 로고
    • The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin
    • BACKMAN JT, KIVISTÖ KT, OLKKOLA KT, NEUVONEN PJ: The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur. J. Clin. Pharmacol. (1998) 54(1):53-58.
    • (1998) Eur. J. Clin. Pharmacol. , vol.54 , Issue.1 , pp. 53-58
    • Backman, J.T.1    Kivistö, K.T.2    Olkkola, K.T.3    Neuvonen, P.J.4
  • 52
    • 0029906407 scopus 로고    scopus 로고
    • The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam
    • AHONEN J, OLKKOLA KT, NEUVONEN PJ: The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam. Clin. Pharmacol. (1996) 10(3):314-318.
    • (1996) Fundam. Clin. Pharmacol. , vol.10 , Issue.3 , pp. 314-318
    • Ahonen, J.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 53
    • 0029878797 scopus 로고    scopus 로고
    • Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam
    • AHONEN J, OLKKOLA KT, NEUVONEN PJ: Lack of effect of the antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther. Drug Monit. (1996) 18(2):124-127.
    • (1996) Ther. Drug Monit. , vol.18 , Issue.2 , pp. 124-127
    • Ahonen, J.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 54
    • 0344303626 scopus 로고    scopus 로고
    • The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers
    • ODA M, KOTEGAWA T, TSUTSUMI K, OHTANI Y, KUWATANI K, NAKANO S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur. J. Clin. Pharmacol. (2003) 59(8-9):615-619.
    • (2003) Eur. J. Clin. Pharmacol. , vol.59 , Issue.8-9 , pp. 615-619
    • Oda, M.1    Kotegawa, T.2    Tsutsumi, K.3    Ohtani, Y.4    Kuwatani, K.5    Nakano, S.6
  • 55
    • 0036001235 scopus 로고    scopus 로고
    • No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam
    • OTSUJI Y, OKUYAMA N, AOSHIMA T et al.: No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Ther. Drug Monit. (2002) 24(3):375-378.
    • (2002) Ther. Drug Monit. , vol.24 , Issue.3 , pp. 375-378
    • Otsuji, Y.1    Okuyama, N.2    Aoshima, T.3
  • 56
    • 0030882158 scopus 로고    scopus 로고
    • Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole
    • KIVISTÖ KT, LAMBERG TS, KANTOLA T, NEUVONEN PJ: Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. (1997) 62(3):348-354.
    • (1997) Clin. Pharmacol. Ther. , vol.62 , Issue.3 , pp. 348-354
    • Kivistö, K.T.1    Lamberg, T.S.2    Kantola, T.3    Neuvonen, P.J.4
  • 57
    • 0031954051 scopus 로고    scopus 로고
    • Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem
    • LUURILA H, KIVISTÖ KT, NEUVONEN PJ: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur. J. Clin. Pharmacol. (1998) 54(2):163-166.
    • (1998) Eur. J. Clin. Pharmacol. , vol.54 , Issue.2 , pp. 163-166
    • Luurila, H.1    Kivistö, K.T.2    Neuvonen, P.J.3
  • 58
    • 0031466520 scopus 로고    scopus 로고
    • Interactions between tacrolimus and antimicrobial agents
    • PATERSON DL, SINGH N: Interactions between tacrolimus and antimicrobial agents. Clin. Infect. Dis. (1997) 25(6):1430-1440.
    • (1997) Clin. Infect. Dis. , vol.25 , Issue.6 , pp. 1430-1440
    • Paterson, D.L.1    Singh, N.2
  • 59
    • 0031939246 scopus 로고    scopus 로고
    • Systemic antifungal agents: Drug interactions of clinical significance
    • ALBENGRES E, LE LOUËT H, TILLEMENT JP: Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. (1998) 18(2):83-97.
    • (1998) Drug Saf. , vol.18 , Issue.2 , pp. 83-97
    • Albengres, E.1    Le Louët, H.2    Tillement, J.P.3
  • 60
    • 0030042485 scopus 로고    scopus 로고
    • Clinically significant drug interactions with cyclosporin: An update. cyclosporine with antimicrobial agents
    • CAMPANA C, REGAZZI MB, BUGGIA I, MOLINARO M: Clinically significant drug interactions with cyclosporin: an update. cyclosporine with antimicrobial agents. Clin. Pharmacokinet. (1996) 30(2):141-179.
    • (1996) Clin. Pharmacokinet. , vol.30 , Issue.2 , pp. 141-179
    • Campana, C.1    Regazzi, M.B.2    Buggia, I.3    Molinaro, M.4
  • 61
    • 0024995451 scopus 로고
    • Cyclosporine and itraconazole in heart and lung transplant recipients
    • KRAMER MR, MARSHALL SE, DENNING DW et al.: Cyclosporine and itraconazole in heart and lung transplant recipients. Ann. Intern. Med. (1990) 113(4):327-329.
    • (1990) Ann. Intern. Med. , vol.113 , Issue.4 , pp. 327-329
    • Kramer, M.R.1    Marshall, S.E.2    Denning, D.W.3
  • 62
    • 0031671850 scopus 로고    scopus 로고
    • Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients
    • BILLAUD EM, GUILLEMAIN R, TACCO F, CHEVALIER P: Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br. J. Clin. Pharmacol. (1998) 46(3):271-272.
    • (1998) Br. J. Clin. Pharmacol. , vol.46 , Issue.3 , pp. 271-272
    • Billaud, E.M.1    Guillemain, R.2    Tacco, F.3    Chevalier, P.4
  • 63
    • 0031660264 scopus 로고    scopus 로고
    • Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole
    • VARIS T, KAUKONEN KM, KIVISTÖ KT, NEUVONEN PJ: Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin. Pharmacol. Ther. (1998) 64(4):363-368.
    • (1998) Clin. Pharmacol. Ther. , vol.64 , Issue.4 , pp. 363-368
    • Varis, T.1    Kaukonen, K.M.2    Kivistö, K.T.3    Neuvonen, P.J.4
  • 64
    • 0034856667 scopus 로고    scopus 로고
    • Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects
    • LEBRUN-VIGNES B, ARCHER VC, DIQUET B et al.: Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br. J. Clin. Pharmacol. (2001) 51(5):443-450.
    • (2001) Br. J. Clin. Pharmacol. , vol.51 , Issue.5 , pp. 443-450
    • Lebrun-Vignes, B.1    Archer, V.C.2    Diquet, B.3
  • 65
    • 0032967254 scopus 로고    scopus 로고
    • Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers
    • VARIS T, KIVISTÖ KT, BACKMAN JT, NEUVONEN PJ: Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol. Toxicol. (1999) 85(1):29-32.
    • (1999) Pharmacol. Toxicol. , vol.85 , Issue.1 , pp. 29-32
    • Varis, T.1    Kivistö, K.T.2    Backman, J.T.3    Neuvonen, P.J.4
  • 66
    • 0033681559 scopus 로고    scopus 로고
    • The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect
    • VARIS T, KIVISTÖ KT, BACKMAN JT, NEUVONEN PJ: The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. Clin. Pharmacol. Ther. (2000) 68(5):487-494.
    • (2000) Clin. Pharmacol. Ther. , vol.68 , Issue.5 , pp. 487-494
    • Varis, T.1    Kivistö, K.T.2    Backman, J.T.3    Neuvonen, P.J.4
  • 67
    • 0034071745 scopus 로고    scopus 로고
    • The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone
    • VARIS T, KIVISTÖ KT, NEUVONEN PJ: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur. J. Clin. Pharmacol. (2000) 56(1):57-60.
    • (2000) Eur. J. Clin. Pharmacol. , vol.56 , Issue.1 , pp. 57-60
    • Varis, T.1    Kivistö, K.T.2    Neuvonen, P.J.3
  • 68
    • 0036795133 scopus 로고    scopus 로고
    • Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P450 3A4 inhibitor itraconazole
    • RAASKA K, NIEMI M, NEUVONEN M, NEUVONEN PJ, KIVISTÖ KT: Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P450 3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. (2002) 72(4):362-369.
    • (2002) Clin. Pharmacol. Ther. , vol.72 , Issue.4 , pp. 362-369
    • Raaska, K.1    Niemi, M.2    Neuvonen, M.3    Neuvonen, P.J.4    Kivistö, K.T.5
  • 69
    • 0030898365 scopus 로고    scopus 로고
    • Itraconazole greatly increases plasma concentrations and effects of felodipine
    • JALAVA KM, OLKKOLA KT, NEUVONEN PJ: Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin. Pharmacol. Ther. (1997) 61(4):410-415.
    • (1997) Clin. Pharmacol. Ther. , vol.61 , Issue.4 , pp. 410-415
    • Jalava, K.M.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 70
    • 0031028102 scopus 로고    scopus 로고
    • Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam
    • AHONEN J, OLKKOLA KT, NEUVONEN PJ: Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur. J. Clin. Pharmacol. (1997) 51(5):415-419.
    • (1997) Eur. J. Clin. Pharmacol. , vol.51 , Issue.5 , pp. 415-419
    • Ahonen, J.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 71
    • 0029981350 scopus 로고    scopus 로고
    • Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism
    • VARHE A, OLKKOLA KT, NEUVONEN PJ: Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br. J. Clin. Pharmacol. (1996) 41(4):319-323.
    • (1996) Br. J. Clin. Pharmacol. , vol.41 , Issue.4 , pp. 319-323
    • Varhe, A.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 72
    • 0029798201 scopus 로고    scopus 로고
    • Effect of fluconazole dose on the extent of fluconazole-triazolam interaction
    • VARHE A, OLKKOLA KT, NEUVONEN PJ: Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br. J. Clin. Pharmacol. (1996) 42(4):465-470.
    • (1996) Br. J. Clin. Pharmacol. , vol.42 , Issue.4 , pp. 465-470
    • Varhe, A.1    Olkkola, K.T.2    Neuvonen, P.J.3
  • 73
    • 0028341698 scopus 로고
    • Fluconazole therapy in transplant recipients receiving FK506
    • MANEZ R, MARTIN M, RAMAN D et al.: Fluconazole therapy in transplant recipients receiving FK506. Transplantation (1994) 57(10):1521-1523.
    • (1994) Transplantation , vol.57 , Issue.10 , pp. 1521-1523
    • Manez, R.1    Martin, M.2    Raman, D.3
  • 76
    • 0027284797 scopus 로고
    • Fluconazole-cyclosporine interaction: A dose-dependent effect?
    • LOPEZ-GIL JA: Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann. Pharmacotherapy (1993) 27(4):427-430.
    • (1993) Ann. Pharmacotherapy , vol.27 , Issue.4 , pp. 427-430
    • Lopez-Gil, J.A.1
  • 77
    • 0029913912 scopus 로고    scopus 로고
    • Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients
    • OSOWSKI CL, DIX SP, LIN LS, MULLINS RE, GELLER RB, WINGARD JR: Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant recipients. Transplantation (1996) 61(8):1268-1272.
    • (1996) Transplantation , vol.61 , Issue.8 , pp. 1268-1272
    • Osowski, C.L.1    Dix, S.P.2    Lin, L.S.3    Mullins, R.E.4    Geller, R.B.5    Wingard, J.R.6
  • 78
    • 0025760346 scopus 로고
    • Effect of fluconazole on disposition of phenytoin
    • BLUM RA, WILTON JH, HILLIGOSS DM et al.: Effect of fluconazole on disposition of phenytoin. Clin. Pharmacol. Ther. (1991) 49(4):420-425.
    • (1991) Clin. Pharmacol. Ther. , vol.49 , Issue.4 , pp. 420-425
    • Blum, R.A.1    Wilton, J.H.2    Hilligoss, D.M.3
  • 79
    • 0031664160 scopus 로고    scopus 로고
    • Update on drug interactions with azole antifungal agents
    • LOMAESTRO BM, PIATEK MA: Update on drug interactions with azole antifungal agents. Ann. Pharmacotherapy (1998) 32(9):915-928.
    • (1998) Ann. Pharmacotherapy , vol.32 , Issue.9 , pp. 915-928
    • Lomaestro, B.M.1    Piatek, M.A.2
  • 80
    • 0344943294 scopus 로고    scopus 로고
    • Voriconazole potentiates warfarin-induced prothrombin time prolongation
    • PURKINS L, WOOD N, KLEINERMANS D, NICHOLS D: Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):24-29.
    • (2003) Br. J. Clin. Pharmacol. , vol.56 , Issue.SUPPL. 1 , pp. 24-29
    • Purkins, L.1    Wood, N.2    Kleinermans, D.3    Nichols, D.4
  • 81
    • 0036227007 scopus 로고    scopus 로고
    • Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients
    • ROMERO AJ, LE POGAMP P, NILSSON LG, WOOD N: Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant recipients. Clin. Pharmacol. Ther. (2002) 71(4):226-234.
    • (2002) Clin. Pharmacol. Ther. , vol.71 , Issue.4 , pp. 226-234
    • Romero, A.J.1    Le Pogamp, P.2    Nilsson, L.G.3    Wood, N.4
  • 82
    • 0036720272 scopus 로고    scopus 로고
    • Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes
    • VENKATARAMANAN R, ZANG S, GAYOWSKI T, SINGH N: Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob. Agents Chemother. (2002) 46(9):3091-3093.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , Issue.9 , pp. 3091-3093
    • Venkataramanan, R.1    Zang, S.2    Gayowski, T.3    Singh, N.4
  • 84
    • 0344943289 scopus 로고    scopus 로고
    • Coadministration of voriconazole and phenytoin: Pharmacokinetic interaction, safety, and toleration
    • PURKINS L, WOOD N, GHAHRAMANI P, LOVE ER, EVE MD, FIELDING A: Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br. J. Clin. Pharmacol. (2003) 56(Suppl. 1):37-44.
    • (2003) Br. J. Clin. Pharmacol. , vol.56 , Issue.SUPPL. 1 , pp. 37-44
    • Purkins, L.1    Wood, N.2    Ghahramani, P.3    Love, E.R.4    Eve, M.D.5    Fielding, A.6
  • 85
    • 0028276695 scopus 로고
    • Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism
    • ANDERSSON T, MINERS JO, VERONESE ME, BIRKETT DJ: Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. (1994) 37(6):597-604.
    • (1994) Br. J. Clin. Pharmacol. , vol.37 , Issue.6 , pp. 597-604
    • Andersson, T.1    Miners, J.O.2    Veronese, M.E.3    Birkett, D.J.4
  • 88
    • 0027102401 scopus 로고
    • The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin
    • DE LANNOY IA, SILVERMAN M: The mdr-1 gene product P-glycoprotein mediates transport of the cardiac glycoside, digoxin. Biochem. Biophys. Res. Comm. (1992) 189(1):551-557.
    • (1992) Biochem. Biophys. Res. Comm. , vol.189 , Issue.1 , pp. 551-557
    • De Lannoy, I.A.1    Silverman, M.2
  • 89
    • 0031443240 scopus 로고    scopus 로고
    • Itraconazole decreases renal clearance of digoxin
    • JALAVA KM, PARTANEN J, NEUVONEN PJ: Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. (1997) 19(6):609-613.
    • (1997) Ther. Drug Monit. , vol.19 , Issue.6 , pp. 609-613
    • Jalava, K.M.1    Partanen, J.2    Neuvonen, P.J.3
  • 91
  • 92
    • 0032779089 scopus 로고    scopus 로고
    • Effect of diclofenac, disulfram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine
    • DAMKIER P, HANSEN LL, BRØSEN K: Effect of diclofenac, disulfram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br. J. Clin. Pharmacol. (1999) 48(6):829-838.
    • (1999) Br. J. Clin. Pharmacol. , vol.48 , Issue.6 , pp. 829-838
    • Damkier, P.1    Hansen, L.L.2    Brøsen, K.3
  • 93
    • 0026467167 scopus 로고
    • Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin
    • DE LANNOY IA, KOREN G, KLEIN J, CHARUK J, SILVERMAN M: Cyclosporin and quinidine inhibition of renal digoxin excretion: evidence for luminal secretion of digoxin. Am. J. Physiol. (1992) 263(4):F613-F622.
    • (1992) Am. J. Physiol. , vol.263 , Issue.4
    • De Lannoy, I.A.1    Koren, G.2    Klein, J.3    Charuk, J.4    Silverman, M.5
  • 94
    • 0038681693 scopus 로고    scopus 로고
    • Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole
    • ULLMAN AJ: Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole. Curr. Med. Res. Opinion (2003) 19(4):263-271.
    • (2003) Curr. Med. Res. Opinion , vol.19 , Issue.4 , pp. 263-271
    • Ullman, A.J.1
  • 95
    • 0037339171 scopus 로고    scopus 로고
    • Caspofungin: The first representative of a new antifungal class
    • LETSCHER-BRU V, HERBRECHT R: Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. (2003) 51(3):513-521.
    • (2003) J. Antimicrob. Chemother. , vol.51 , Issue.3 , pp. 513-521
    • Letscher-Bru, V.1    Herbrecht, R.2
  • 97
    • 3543095658 scopus 로고    scopus 로고
    • Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections
    • SANZ-RODRIGUEZ C, LOPEZ-DUARTE M, JURADO M et al.: Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant. (2004) 34(1):13-20.
    • (2004) Bone Marrow Transplant. , vol.34 , Issue.1 , pp. 13-20
    • Sanz-Rodriguez, C.1    Lopez-Duarte, M.2    Jurado, M.3
  • 98
    • 7244258914 scopus 로고    scopus 로고
    • Potential for interactions between caspofungin and nelfinavir or rifampin
    • STONE JA, MIGOYA EM, HICKEY L et al.: Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. (2004) 48:4306-4314.
    • (2004) Antimicrob. Agents Chemother. , vol.48 , pp. 4306-4314
    • Stone, J.A.1    Migoya, E.M.2    Hickey, L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.